Captor Capital Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 3/6
Captor Capital has been growing earnings at an average annual rate of 43.8%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 29.8% per year. Captor Capital's return on equity is 38.3%, and it has net margins of 33%.
Anahtar bilgiler
43.8%
Kazanç büyüme oranı
50.7%
EPS büyüme oranı
Pharmaceuticals Sektör Büyümesi | 7.3% |
Gelir büyüme oranı | 29.8% |
Özkaynak getirisi | 38.3% |
Net Marj | 33.0% |
Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Gelir ve Gider Dağılımı
Captor Capital nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Jun 24 | 59 | 19 | 13 | 0 |
31 Mar 24 | 37 | -11 | 16 | 0 |
31 Dec 23 | 36 | -15 | 22 | 0 |
30 Sep 23 | 38 | -15 | 22 | 0 |
30 Jun 23 | 40 | -12 | 23 | 0 |
31 Mar 23 | 42 | -13 | 24 | 0 |
31 Dec 22 | 42 | -8 | 20 | 0 |
30 Sep 22 | 39 | -10 | 19 | 0 |
30 Jun 22 | 37 | -14 | 20 | 0 |
31 Mar 22 | 33 | -14 | 18 | 0 |
31 Dec 21 | 28 | -10 | 16 | 0 |
30 Sep 21 | 24 | -8 | 15 | 0 |
30 Jun 21 | 19 | -10 | 12 | 0 |
31 Mar 21 | 16 | -6 | 11 | 0 |
31 Dec 20 | 15 | -5 | 10 | 0 |
30 Sep 20 | 13 | -15 | 10 | 0 |
30 Jun 20 | 13 | -25 | 11 | 0 |
31 Mar 20 | 12 | -33 | 11 | 0 |
31 Dec 19 | 15 | -65 | 10 | 0 |
30 Sep 19 | 13 | -58 | 8 | 0 |
30 Jun 19 | 9 | -48 | 11 | 0 |
31 Mar 19 | 6 | -46 | 14 | 0 |
31 Dec 18 | 4 | -3 | 12 | 0 |
30 Sep 18 | 4 | 0 | 12 | 0 |
30 Jun 18 | 4 | 3 | 5 | 0 |
31 Mar 18 | 0 | 4 | 1 | 0 |
31 Dec 17 | 1 | 4 | 1 | 0 |
30 Sep 17 | 1 | 4 | 1 | 0 |
30 Jun 17 | 2 | 5 | 1 | 0 |
31 Mar 17 | 5 | 8 | 1 | 0 |
31 Dec 16 | 0 | -1 | 1 | 0 |
30 Sep 16 | 0 | -1 | 1 | 0 |
30 Jun 16 | 0 | -2 | 2 | 0 |
31 Mar 16 | -1 | -2 | 1 | 0 |
31 Dec 15 | -2 | -4 | 2 | 0 |
30 Sep 15 | -1 | -4 | 2 | 0 |
30 Jun 15 | -2 | -4 | 2 | 0 |
31 Mar 15 | -1 | -3 | 2 | 0 |
31 Dec 14 | 0 | -3 | 1 | 0 |
30 Sep 14 | 0 | -3 | 2 | 0 |
30 Jun 14 | 0 | -2 | 2 | 0 |
31 Mar 14 | -1 | -3 | 3 | 0 |
31 Dec 13 | -12 | -11 | 3 | 0 |
Kaliteli Kazançlar: NMV has a high level of non-cash earnings.
Büyüyen Kar Marjı: NMV became profitable in the past.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: NMV has become profitable over the past 5 years, growing earnings by 43.8% per year.
Büyüme Hızlandırma: NMV has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Kazançlar vs. Sektör: NMV has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Özkaynak Getirisi
Yüksek ROE: NMV's Return on Equity (38.3%) is considered high.